X-linked retinitis pigmentosa
Information
- Disease name
- X-linked retinitis pigmentosa
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06333249 | Active, not recruiting | Phase 2 | A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) | April 13, 2021 | February 2027 |
| NCT03316560 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | April 16, 2018 | March 2025 |
| NCT04312672 | Active, not recruiting | Long-term Follow-up Gene Therapy Study for RPGR- XLRP | July 31, 2017 | November 18, 2026 | |
| NCT04517149 | Active, not recruiting | Phase 1/Phase 2 | 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | June 9, 2020 | May 2029 |
| NCT04671433 | Active, not recruiting | Phase 3 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | December 4, 2020 | September 20, 2024 |
| NCT04794101 | Active, not recruiting | Phase 3 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | December 4, 2020 | December 19, 2029 |
| NCT03252847 | Completed | Phase 1/Phase 2 | Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) | July 14, 2017 | November 18, 2021 |
| NCT03314207 | Completed | Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) | December 1, 2017 | February 10, 2022 | |
| NCT03116113 | Completed | Phase 1/Phase 2 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 | March 8, 2017 | November 18, 2020 |
| NCT04926129 | Completed | Natural History of the Progression of X-Linked Retinitis Pigmentosa | September 13, 2017 | December 16, 2022 | |
| NCT04868916 | Completed | An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa | July 26, 2021 | April 23, 2024 | |
| NCT06275620 | Enrolling by invitation | Phase 2 | A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | November 14, 2023 | August 2029 |
| NCT03584165 | Enrolling by invitation | Phase 3 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa | June 4, 2018 | June 4, 2026 |
| NCT05874310 | Recruiting | Early Phase 1 | Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa | February 1, 2023 | November 1, 2027 |
| NCT04850118 | Recruiting | Phase 2/Phase 3 | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | March 14, 2024 | October 2029 |
| NCT05926583 | Recruiting | Phase 3 | A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa | September 12, 2023 | October 9, 2029 |